tumour marker

(redirected from cancer marker)

tumour marker

Any specific substance present in increased amounts in serum that may be used for early cancer (CA) detection. Most tumour markers are nonspecific and of little use as screening tools; they may be used to detect recurrence (e.g., CEA in patients with known colorectal and other CAs).  

Examples
Oncofoetal proteins (alpha-fetoprotein) for hepatic carcinoma; CA125 for ovarian CA; CEA for ovarian, lung, breast, pancreas, GI tract CAs; PSA for prostate CA.

tu·mor mark·er

(tū'mŏr mahr'kĕr)
A substance released into the circulation by tumor tissue; its detection in the serum indicates the presence and specific type of tumor.
Synonym(s): tumour marker.

tu·mor mark·er

(tū'mŏr mahr'kĕr)
A substance released into the circulation by tumor tissue; its detection in the serum indicates the presence and specific type of tumor.
Synonym(s): tumour marker, tumour marker.
References in periodicals archive ?
Pembrolizumab (anti-PDI) is the first cancer drug based on a predictive cancer marker, rather than tumour type, to be approved by the US FDA.
In the case of a colon cancer marker, evaluating whether chemotherapy is the right decision depends on the relative benefits and harms of chemotherapy.
After the first four months of chemotherapy, my cancer marker was in the normal range.
2] With the discovery of this new breast cancer marker, it will be possible to develop new and more effective therapeutic drugs based on KLF6-SV1 that can potentially reduce mortalities due to breast cancer.
Even if it does not, it could provide doctors with a useful new cancer marker.
Scientists have long been investigating a blood test for an ovarian cancer marker called CA-125, as well as TVU.
This highlights the importance of an inexpensive, reliable cancer marker test and monitoring tool which BioCurex believes could be fulfilled by its RECAF blood test.
Successful completion of this financing will provide us with capital to continue our development efforts, pursue regulatory approvals and commercialization of the point-of-care rapid test format of our RECAF(TM) cancer marker testing technology, and to commence marketing our other test formats in sectors where regulatory approvals are not required.
In a more recent study evaluating an ovarian cancer marker panel that included leptin, prolactin, osteopontin, IGF-II, macrophage migration inhibitory factor, and CA 125, only CA 125, osteopontin, and IGF-II levels differed significantly between ovarian cancer patients and controls with benign ovarian disease (Anticancer Res.
Once upon a time, a cancer marker that showed initial promise was embraced for use in insurance screening by a prominent carrier.
Under the terms of the agreement, Clarient obtained an exclusive license to HDC's prostate cancer marker and plans to immediately initiate the commercialization process for the test.